文献速递外周动脉疾病

急性或非急性肢体缺血血运重建后双通路抑制与双联抗血小板治疗的倾向评分匹配分析

Dual pathway inhibition versus dual antiplatelet therapy in patients with acute or nonacute limb ischemia: A propensity score-matched analysis from the RESOLVE study.
PubMed 文献 · J Vasc Surg · 2026-09-07

本研究基于RESOLVE前瞻性多中心注册研究,经倾向评分匹配109对患者,比较腔内血运重建后双通路抑制(DPI)与双联抗血小板治疗(DAPT)的24个月结局。结果显示DPI组主要不良事件、主要不良肢体事件及全因死亡发生率均显著低于DAPT组,两组均未观察到 major bleeding。

要点

  • 肢体缺血腔内血运重建后,DPI较DAPT显著降低24个月MAE、MALE和全因死亡。
  • 两组均未观察到 major bleeding 事件。
  • SVS runoff评分>10和慢性肢体威胁性缺血患者从DPI获益更明显。

核心结论

  • 在倾向评分匹配分析中,DPI与DAPT相比,24个月MAE、MALE和全因死亡发生率显著更低,两组均未观察到 major bleeding。

研究设计与样本

  • 前瞻性多中心观察性研究,数据来自RESOLVE注册研究,采用倾向评分匹配比较腔内血运重建后接受DPI或DAPT的患者,匹配后分析109对。

主要发现

  • DPI组24个月MAE发生率为11.47%,DAPT组为28.45%(HR=2.83,P<.01)。
  • DPI组MALE发生率为16.83%,DAPT组为28.40%(HR=1.83,P=.04)。
  • DPI组全因死亡发生率为2.94%,DAPT组为11.65%(HR=4.28,P=.02)。
  • MACE在DPI组呈更低趋势(2.00% vs 7.77%;HR=4.22,P=.07)。
  • 两组均未观察到 major bleeding 事件。

关键数值与推荐

  • 主要终点为24个月MAE,定义为复发性急性肢体缺血、大截肢、心肌梗死、缺血性卒中或心血管死亡。
  • 次要终点包括MALE、MACE和全因死亡。
  • 改良SVS runoff评分>10和慢性肢体威胁性缺血预测DPI获益更大(交互作用P=.020和.031)。

临床怎么用

  • 对于腔内血运重建后的肢体缺血患者,尤其是SVS runoff评分>10或慢性肢体威胁性缺血者,DPI可能较DAPT提供更优的24个月疗效。
  • 研究未观察到 major bleeding 事件,但需在随机对照试验中进一步确认DPI的疗效与安全性。

局限性

  • 本研究为观察性注册研究,即使采用倾向评分匹配仍可能存在残余混杂。
  • 作者指出DPI的有利疗效特征需进一步随机对照试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Real-world evidence comparing dual-pathway inhibition (DPI) with dual antiplatelet therapy (DAPT) after endovascular revascularization for acute or nonacute limb ischemia is limited. This study aims to compare the 24-month effectiveness and safety outcomes of DPI vs DAPT in this setting. METHODS: This prospective, multicenter observational study, drawing data from the RESOLVE registry, used propensity score matching (PSM) to compare outcomes in patients receiving either DPI or DAPT after endovascular revascularization. The primary end point was 24-month major adverse events (MAE), defined as recurrent acute limb ischemia, major amputation, myocardial infarction, ischemic stroke, or cardiovascular death. Secondary end points included major adverse limb events (MALE), major adverse cardiovascular events (MACE), and all-cause death. RESULTS: After PSM, 109 matched pairs were analyzed. The DPI group had a significantly lower 24-month MAE incidence than the DAPT group (11.47% vs 28.45%; hazard ratio [HR] = 2.83; P < .01). The DPI group also showed lower rates of MALE (16.83% vs 28.40%; HR = 1.83; P = .04) and all-cause death (2.94% vs 11.65%; HR = 4.28; P = .02). MACE showed a trend toward lower incidence with DPI (2.00% vs 7.77%; HR = 4.22; P = .07). No major bleeding events were observed in either group. A modified Society for Vascular Surgery runoff score >10 and chronic limb-threatening ischemia predicted greater benefit from DPI (P for interaction = .020 and .031, respectively). CONCLUSIONS: In this PSM analysis, DPI was associated with significantly lower 24-month rates of MAE, MALE, and all-cause death compared with DAPT. No major bleeding events were observed in either group. These findings suggest a potentially favorable efficacy profile for DPI but warrant confirmation in further randomized controlled trials.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang Y, Liu Y, He C, et al. Dual pathway inhibition versus dual antiplatelet therapy in patients with acute or nonacute limb ischemia: A propensity score-matched analysis from the RESOLVE study. J Vasc Surg. 2026. PMID: 42705505. doi:10.1016/j.jvs.2026.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。